Literature DB >> 21117521

Use of endocrine hormones for treating depression.

Robert H Howland1.   

Abstract

Disturbances in some endocrine hormones have been implicated in the pathophysiology of depression. Some of these hormones (and drugs that affect hormone function) have been used as therapeutic agents for the treatment of depression, especially adrenal, thyroid, and gonadal axis hormones. Open-label and controlled studies of various drugs that directly suppress or inhibit adrenal axis function have shown some benefit for the treatment of major depression, including treatment-resistant depression. Thyroid hormone augmentation is effective for nonresponders to antidepressant agents, although it has not been studied extensively. Estrogen may improve mild mood symptoms in perimenopausal women but may not be effective alone for major depression. Evidence of the antidepressant effects of testosterone in men is inconsistent, with mixed results from controlled studies. The adrenal steroid hormone dehydroepiandrosterone has an important role in mood regulation and may have significant antidepressant effects. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21117521     DOI: 10.3928/02793695-20101105-01

Source DB:  PubMed          Journal:  J Psychosoc Nurs Ment Health Serv        ISSN: 0279-3695            Impact factor:   1.098


  3 in total

Review 1.  Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience.

Authors:  M C Flux; Christopher A Lowry
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

Review 2.  Pharmacological approaches to the challenge of treatment-resistant depression.

Authors:  Dawn F Ionescu; Jerrold F Rosenbaum; Jonathan E Alpert
Journal:  Dialogues Clin Neurosci       Date:  2015-06       Impact factor: 5.986

3.  Generic switching and non-persistence among medicine users: a combined population-based questionnaire and register study.

Authors:  Jette Rathe; Morten Andersen; Dorte Ejg Jarbøl; René dePont Christensen; Jesper Hallas; Jens Søndergaard
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.